Table 4.
Base case results for treatment options relative to FMT NGT for rCDI.
| Treatment option | Expected cost per patient (UK £ 2018) | Difference in Costs (UK £ 2018) | QALYs | Difference in QALYs | ICER b |
|---|---|---|---|---|---|
| FMT – NGT a | 8877 | - | 0.645 | - | - |
| FMT – colonoscopy | 11,716 | +2839 | 0.657 | +0.012 | 242,514 |
| Fidaxomicin | 14,399 | +5521 | 0.577 | −0.068 | Dominated |
| Vancomycin | 17,279 | +8402 | 0.513 | −0.132 | Dominated |
Abbreviations: FMT, Faecal Microbiota Transplantation; NGT, Nasogastric Tube; ICER, Incremental Cost Effectiveness Ratio; QALYs, Quality Adjusted Life Years.
a
This represents the least costly option and the baseline with which subsequent options are compared.
b
Incremental cost effectiveness ratio expressed as the additional cost per additional QALY.